CIR. Cumulative incidence of relapse from the time of CR among all 382 patients (A) and 303 intermediate- and high-risk patients (B), according to whether they received anthracycline monochemotherapy consolidation (LPA96 study) or risk-adapted consolidation (LPA99 study). (C) CIR of all patients according to both the risk group and the trial.